Abivax Shares Plunge 32% Following New Drug Data Release
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
Source: CNBC
Abivax SA's stock price fell by 27.52% in pre-market trading, crossing below the 5-day SMA, following the release of new drug efficacy data for its lead drug, Obefazimod.
The recent data indicated a remission rate of approximately 40% in a 44-week maintenance study for ulcerative colitis, but the report of cancer cases raised investor concerns, leading to a significant drop in stock price. Despite a previous surge of nearly 1,700% in 2025, the stock's decline reflects ongoing worries about the drug's safety profile and its potential impact on future valuations. Analysts suggest that while the drug shows promise, the cancer signal could hinder investor confidence and affect the company's stock price in the long term.
The implications of this volatility are significant for Abivax, as it navigates the challenges of maintaining investor trust while preparing for future trials and potential FDA submissions. The market's reaction underscores the delicate balance biotech firms must strike between promising clinical results and safety concerns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 129.690
Low
131.00
Averages
150.71
High
175.00
Current: 129.690
Low
131.00
Averages
150.71
High
175.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abivax Shares Plunge 32% Following New Drug Data Release
- Drug Efficacy Data: Abivax's lead drug obefazimod demonstrated a remission rate of approximately 40% in a 44-week maintenance study for ulcerative colitis, although cancer cases were reported, which investigators deemed unrelated to treatment, indicating the drug's potential efficacy.
- Market Reaction: Following the data release, Abivax's stock plummeted 32%, reflecting investor concerns over the cancer signal, despite the stock having surged nearly 1,700% in 2025, with a recent decline of over 27% prior to the announcement.
- Industry Analysis: Analysts noted that while obefazimod shows promising efficacy, the cancer signal could create a lasting overhang on the company's stock price, especially given the absence of other value-inflecting data events in the coming year.
- Acquisition Potential: Abivax is viewed as a prime takeover target, with ongoing speculation about interest from big pharma, and the CEO expressed confidence that upcoming key trial data could secure better terms for future partnerships.
See More
Jefferies Downgrades Abivax Amid Cancer Signal Concerns
- Rating Downgrade: Jefferies downgraded Abivax from ‘Buy’ to ‘Hold’ and slashed the price target from $160 to $90, indicating a potential 30% downside from Monday's closing price, reflecting a cautious market outlook on the company's future performance.
- Clinical Trial Results: While Abivax's late-stage trial for ulcerative colitis demonstrated strong efficacy with 51% of patients achieving clinical remission at Week 44 using 25 mg and 50 mg doses of Obefazimod, a small number of skin cancer and other malignancy cases in the higher-dose group raised investor concerns about safety.
- Market Reaction: Following the cancer signal, Abivax's shares plummeted 32% in premarket trading on Tuesday and are on track to breach their 200-day moving average for the first time since July 2025, indicating a significant loss of investor confidence in the company's prospects.
- Investor Sentiment Shift: Despite the stock's decline, retail sentiment on Stocktwits shifted from ‘neutral’ to ‘extremely bullish’, with message volumes surging by 14,500% over a 24-hour period, suggesting some investors view the drop as an “overreaction” and are advocating for buying on dips.
See More
Abivax Drug Trial Results Mixed Despite Positive Efficacy
- Clinical Trial Results: Abivax announced positive Phase 3 maintenance trial results for its ulcerative colitis drug obefazimod, achieving a remission rate of approximately 40%; however, cancer cases were reported in the higher dose group, introducing uncertainty to the drug's prospects.
- Cancer Signal Impact: Although the company stated that the cancer cases were unrelated to treatment, Jefferies analysts noted that this signal could negatively affect investor sentiment, especially given the absence of other value-inflecting data events over the next year.
- Market Reaction: Following this news, Abivax's stock plunged over 32% in premarket trading, reflecting market concerns over potential risks and a significant loss of investor confidence in the drug's future.
- Future Outlook: While analysts believe a reasonable explanation for the cancer cases is plausible, they caution that this issue is unlikely to be easily dismissed, potentially impacting Abivax's long-term strategy and financing capabilities.
See More
Abivax Shares Plunge 32% Amid Cancer Risk Concerns
- Stock Plunge: Abivax's shares tumbled as much as 32% on Tuesday due to concerns over potential cancer risks associated with its lead drug, despite demonstrating clinically meaningful efficacy in ulcerative colitis trials.
- Clinical Trial Findings: The drug obefazimod showed a remission rate of approximately 40% in a 44-week maintenance study, but three cancer cases were reported in the higher dose group, which investigators deemed unrelated to treatment.
- Market Reaction: Analysts noted that the cancer signal complicates matters, suggesting that even if deemed unrelated, the overhang will likely pressure the stock, especially given the absence of other value-inflecting data events over the next year.
- Acquisition Potential: Abivax is viewed as a prime takeover target, with speculation surrounding interest from big pharma, although the CEO indicated that the company is not in a rush to finalize a deal, believing that key June trial data could secure better partnership terms.
See More
Abivax Reports Landmark Phase 3 Trial Results for Obefazimod in Ulcerative Colitis
- Trial Success: Abivax SA's Phase 3 ABTECT maintenance trial evaluated Obefazimod in 580 adults with moderately to severely active ulcerative colitis, revealing clinical remission rates of 50.8% and 51.3% for the 25 mg and 50 mg doses respectively, significantly surpassing the placebo rate of 10.4%, indicating strong potential for maintaining remission.
- Safety Profile: The safety data were consistent with prior studies, with no new safety signals reported, validating Obefazimod's long-term safety and enhancing its competitive edge in the market for ulcerative colitis treatments.
- Future Plans: Abivax intends to submit a New Drug Application (NDA) to the FDA in late Q4 2026 for Obefazimod and expects topline results from its Phase 2b induction trial in Crohn's disease by mid-2027, which will provide crucial support for the company's growth trajectory.
- Market Volatility: Despite Abivax's stock price fluctuating significantly over the past year, peaking at $148.83, it closed at $129.69 in the latest trading session, reflecting positive market sentiment towards its clinical results, although it dropped to $93.03 in after-hours trading, a decline of 28.27%.
See More
European Equities Rebound as Investors Await Key Economic Data
- Market Rebound: The pan-European Stoxx 600 index rose by 0.7% as investors await key economic data regarding the impact of the U.S.-Iran war, indicating cautious optimism about future economic recovery.
- Corporate News: Shares of French biotech firm Abivax plummeted 28% in early trading after several patients in its ulcerative colitis trial developed cancer, with analysts suggesting this poses significant pressure on the company's future prospects.
- Inflation Data Expectations: Investors are looking forward to the upcoming flash inflation data for the eurozone, which saw inflation rise to 3% in April from 2.6% in March, significantly exceeding the ECB's 2% target, highlighting the impact of surging energy prices.
- Geopolitical Risks: With U.S.-Iran negotiations stalled and the Strait of Hormuz effectively closed, the EU faces economic pressures, prompting calls for a seat at the negotiating table to address ongoing geopolitical uncertainties.
See More
Abivax Shares Plunge 32% Following New Drug Data Release
- Drug Efficacy Data: Abivax's lead drug obefazimod demonstrated a remission rate of approximately 40% in a 44-week maintenance study for ulcerative colitis, although cancer cases were reported, which investigators deemed unrelated to treatment, indicating the drug's potential efficacy.
- Market Reaction: Following the data release, Abivax's stock plummeted 32%, reflecting investor concerns over the cancer signal, despite the stock having surged nearly 1,700% in 2025, with a recent decline of over 27% prior to the announcement.
- Industry Analysis: Analysts noted that while obefazimod shows promising efficacy, the cancer signal could create a lasting overhang on the company's stock price, especially given the absence of other value-inflecting data events in the coming year.
- Acquisition Potential: Abivax is viewed as a prime takeover target, with ongoing speculation about interest from big pharma, and the CEO expressed confidence that upcoming key trial data could secure better terms for future partnerships.
See More
Jefferies Downgrades Abivax Amid Cancer Signal Concerns
- Rating Downgrade: Jefferies downgraded Abivax from ‘Buy’ to ‘Hold’ and slashed the price target from $160 to $90, indicating a potential 30% downside from Monday's closing price, reflecting a cautious market outlook on the company's future performance.
- Clinical Trial Results: While Abivax's late-stage trial for ulcerative colitis demonstrated strong efficacy with 51% of patients achieving clinical remission at Week 44 using 25 mg and 50 mg doses of Obefazimod, a small number of skin cancer and other malignancy cases in the higher-dose group raised investor concerns about safety.
- Market Reaction: Following the cancer signal, Abivax's shares plummeted 32% in premarket trading on Tuesday and are on track to breach their 200-day moving average for the first time since July 2025, indicating a significant loss of investor confidence in the company's prospects.
- Investor Sentiment Shift: Despite the stock's decline, retail sentiment on Stocktwits shifted from ‘neutral’ to ‘extremely bullish’, with message volumes surging by 14,500% over a 24-hour period, suggesting some investors view the drop as an “overreaction” and are advocating for buying on dips.
See More
Abivax Drug Trial Results Mixed Despite Positive Efficacy
- Clinical Trial Results: Abivax announced positive Phase 3 maintenance trial results for its ulcerative colitis drug obefazimod, achieving a remission rate of approximately 40%; however, cancer cases were reported in the higher dose group, introducing uncertainty to the drug's prospects.
- Cancer Signal Impact: Although the company stated that the cancer cases were unrelated to treatment, Jefferies analysts noted that this signal could negatively affect investor sentiment, especially given the absence of other value-inflecting data events over the next year.
- Market Reaction: Following this news, Abivax's stock plunged over 32% in premarket trading, reflecting market concerns over potential risks and a significant loss of investor confidence in the drug's future.
- Future Outlook: While analysts believe a reasonable explanation for the cancer cases is plausible, they caution that this issue is unlikely to be easily dismissed, potentially impacting Abivax's long-term strategy and financing capabilities.
See More
Abivax Shares Plunge 32% Amid Cancer Risk Concerns
- Stock Plunge: Abivax's shares tumbled as much as 32% on Tuesday due to concerns over potential cancer risks associated with its lead drug, despite demonstrating clinically meaningful efficacy in ulcerative colitis trials.
- Clinical Trial Findings: The drug obefazimod showed a remission rate of approximately 40% in a 44-week maintenance study, but three cancer cases were reported in the higher dose group, which investigators deemed unrelated to treatment.
- Market Reaction: Analysts noted that the cancer signal complicates matters, suggesting that even if deemed unrelated, the overhang will likely pressure the stock, especially given the absence of other value-inflecting data events over the next year.
- Acquisition Potential: Abivax is viewed as a prime takeover target, with speculation surrounding interest from big pharma, although the CEO indicated that the company is not in a rush to finalize a deal, believing that key June trial data could secure better partnership terms.
See More
Abivax Reports Landmark Phase 3 Trial Results for Obefazimod in Ulcerative Colitis
- Trial Success: Abivax SA's Phase 3 ABTECT maintenance trial evaluated Obefazimod in 580 adults with moderately to severely active ulcerative colitis, revealing clinical remission rates of 50.8% and 51.3% for the 25 mg and 50 mg doses respectively, significantly surpassing the placebo rate of 10.4%, indicating strong potential for maintaining remission.
- Safety Profile: The safety data were consistent with prior studies, with no new safety signals reported, validating Obefazimod's long-term safety and enhancing its competitive edge in the market for ulcerative colitis treatments.
- Future Plans: Abivax intends to submit a New Drug Application (NDA) to the FDA in late Q4 2026 for Obefazimod and expects topline results from its Phase 2b induction trial in Crohn's disease by mid-2027, which will provide crucial support for the company's growth trajectory.
- Market Volatility: Despite Abivax's stock price fluctuating significantly over the past year, peaking at $148.83, it closed at $129.69 in the latest trading session, reflecting positive market sentiment towards its clinical results, although it dropped to $93.03 in after-hours trading, a decline of 28.27%.
See More
European Equities Rebound as Investors Await Key Economic Data
- Market Rebound: The pan-European Stoxx 600 index rose by 0.7% as investors await key economic data regarding the impact of the U.S.-Iran war, indicating cautious optimism about future economic recovery.
- Corporate News: Shares of French biotech firm Abivax plummeted 28% in early trading after several patients in its ulcerative colitis trial developed cancer, with analysts suggesting this poses significant pressure on the company's future prospects.
- Inflation Data Expectations: Investors are looking forward to the upcoming flash inflation data for the eurozone, which saw inflation rise to 3% in April from 2.6% in March, significantly exceeding the ECB's 2% target, highlighting the impact of surging energy prices.
- Geopolitical Risks: With U.S.-Iran negotiations stalled and the Strait of Hormuz effectively closed, the EU faces economic pressures, prompting calls for a seat at the negotiating table to address ongoing geopolitical uncertainties.
See More
